Background: Adolescent women, 15-19 yo, have the highest rates of CT infection. As the majority of chlamydia infections are asymptomatic, screening is imperative. Although the CDC recommends screening on a yearly basis for adolescent women, there have been increasing rates of CT infections over the preceding two years. The number may actually be higher as many women at risk are still not being tested. Point of care tests (POCT) for STDs, including CT, are currently under development. Following the example of pregnancy testing, the Food and Drug Administration (FDA) has considered whether such a test, if available, could be made available OTC. There is precedent - an OTC HIV test was approved by the FDA in 2012, but appears to be underutilized due to cost and accessibility. Objectives: Ascertain adolescents’ knowledge about CT infection to determine if an OTC test would be purchased and whether adolescents would seek treatment for themselves and their partners. Methods: A prospective study based on an anonymous 12-item survey to measure patient knowledge and acceptability was distributed to adolescents and young adults attending the adolescent medicine clinics. Questions included demographics, sexual orientation, knowledge of CT, previous infection, would they refer partner to care. Results: Survey results from 65 adolescents and young adults were reviewed and analyzed. They ranged from 14-21 years old with 77% female and 23% male respondents. About 75% of adolescents had inadequate or no knowledge of how CT is acquired or complications. Although all the respondents with prior CT infection obtained treatment, 18% of females did not inform their sexual partner. About 45% of respondents would purchase the test if available, 70% would be willing to pay $30 or less. More than 90% of respondents would go see a doctor if the test was positive and would inform their sexual partner. Conclusion: These preliminary results suggest that there would be a high level of acceptance of potential OTC testing for CT among adolescents. However, many did not have adequate knowledge of the risks of infection. Although, more than 90% stated they would inform their partner if the test was positive and seek care, 18% of females who had CT infection in the past did not inform their partners. Though availability of an OTC assay for CT may increase testing in adolescents, issues still remain: How will we insure that individuals will seek care if the test is positive? How will we insure linkage to care or that they will inform their sexual partner? Will use of these tests lead to loss of important surveillance data? Most importantly, the results of this survey re-emphasize the need for education on the risks of CT infection in this population.